4 research outputs found
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
Agroecology and sustainability in the Didactic Garden of the Faculty of Education -CFP of the Complutense University of Madrid
Con este proyecto se pretende potenciar el uso de los espacios verdes de la UCM, en especial el
Huerto DidĂĄctico de la Facultad de EducaciĂłn, para trabajar con el alumnado de Magisterio la
alimentaciĂłn saludable y sostenibleDepto. de DidĂĄctica de las Ciencias Experimentales , Sociales y MatemĂĄticasDepto. de DidĂĄctica de las Lenguas, Artes y EducaciĂłn FĂsicaFac. de EducaciĂłnFALSEsubmitte
Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort
[Objective] To identify factors related to a poor health-related and global quality of life (QoL) in a cohort of non-demented Parkinson's disease (PD) patients and compare to a control group.[Methods] The data correspond to the baseline evaluation of the COPPADIS-2015 Study, an observational, 5-year follow-up, multicenter, evaluation study. Three instruments were used to assess QoL: (1) the 39-item Parkinson's disease Questionnaire (PDQ-39), (2) a subjective rating of global QoL (PQ-10), and (3) the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Multiple linear regression methods were used to evaluate the direct impact of different variables on these QoL measures.[Results] QoL was worse in PD patients (nâŻ=âŻ692; 62.6âŻÂ±âŻ8.9 years old, 60.3% males) than controls (nâŻ=âŻ206; 61âŻÂ±âŻ8.3 years old, 49.5% males): PDQ-39, 17.1âŻÂ±âŻ13.5 vs 4.4âŻÂ±âŻ6.3 (pâŻ<âŻ0.0001); PQ-10, 7.3âŻÂ±âŻ1.6 vs 8.1âŻÂ±âŻ1.2 (pâŻ<âŻ0.0001); EUROHIS-QOL8, 3.8âŻÂ±âŻ0.6 vs 4.2âŻÂ±âŻ0.5 (pâŻ<âŻ0.0001). A high correlation was observed between PDQ-39 and Non-Motor Symptoms Scale (NMSS) (râŻ=âŻ0.72; pâŻ<âŻ0.0001), and PDQ-39 and Beck Depression Inventory-II (BDI-II) (râŻ=âŻ0.65; pâŻ<âŻ0.0001). For health-related QoL (PDQ-39), non-motor symptoms burden (NMSS), mood (BDI-II), and gait problems (Freezing Of Gait Questionnaire [FOGQ]) provided the highest contribution to the model (ÎČâŻ=âŻ0.32, 0.28, and 0.27, respectively; pâŻ<âŻ0.0001); whereas mood and gait problems contributed the most to global QoL (PQ-10, ÎČâŻ=âŻ-0.46 and â0.21, respectively; EUROHIS-QOL8, ÎČâŻ=âŻ-0.44 and â0.23, respectively).[Conclusions] QoL is worse in PD patients than in controls. Mood, non-motor symptoms burden, and gait problems seem to be the most relevant factors affecting health-related and global perceived QoL in non-demented PD patients.Peer reviewe